Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. (Q38941215)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. |
scientific article |
Statements
Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer (English)
Ion Cristóbal
Rebeca Manso
Cristina Caramés
Sandra Zazo
Juan Madoz-Gúrpide
Jesús García-Foncillas
11 November 2014